Global Bladder Cancer Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Bladder Cancer Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Bladder cancer is a disease in which cells in the urinary bladder start growing abnormally and uncontrollably. The main types of bladder cancer are transitional cell carcinomas (also known as urothelial carcinomas), which begins in the cells that line the inside of the bladder. Rarer bladder cancers include squamous cell carcinomas (originating from flat-shaped cells), adenocarcinomas (from mucus-secreting gland cells), small cell carcinoma (from nerve-like neuroendocrine cells) and sarcomas (from the bladders muscle cells).

Market Overview:

The latest research study on the global Bladder Cancer market finds that the global Bladder Cancer market reached a value of USD 3886.47 million in 2022. It’s expected that the market will achieve USD 13709.57 million by 2028, exhibiting a CAGR of 23.38% during the forecast period.

The raging COVID-19 has plunged the global economic environment into a depression. The impact of COVID-19 on the bladder cancer industry will involve all major links and all entities of the industry chain. In the short term, the outbreak of the epidemic has prompted countries around the world to implement comprehensive traffic control and other measures. This poses a certain threat to the supply chain of bladder cancer drugs. This is mainly reflected in the impact of the epidemic on the procurement of raw materials for the bladder cancer industry. Due to the limited production and poor logistics of raw material suppliers, the procurement of raw materials is facing difficulties, but with the progress of the resumption of work and production, this situation will be effectively alleviated.

From the perspective of bladder cancer companies, the main reason is to increase cost pressure. The outbreak of COVID-19 has put companies under pressure from tight cash flow, supply chain disruption, and a general decline in market supply and demand. Most companies expect a sharp drop in revenue. Employee wages, loan repayments and rental expenses are the main cost pressures for business operations. Especially for SMEs, paying staff wages has become the biggest cost pressure. In contrast, workers at large companies face relatively less wage pressure.

From the downstream point of view, the impact of the epidemic on downstream customers of bladder cancer is comprehensive. The COVID-19 pandemic has impacted healthcare delivery globally since December 2019. The COVID-19 pandemic has impacted oncological approaches in urologic oncology and has led to delays in surgical treatment of bladder cancer. At the same time, the pandemic has negatively impacted both new diagnoses and surveillance of previously treated bladder cancer. Intravesical BCG therapy has been delayed due to the COVID-19 pandemic and has resulted in poor outcomes for patients with high-risk non-muscle-invasive bladder cancer. With the increase in vaccination rates in various places and the gradual control of the epidemic, the treatment of bladder cancer patients will gradually resume.

The risk of drug development failure

For Bladder Cancer drug research and development companies, they are bound to face the risk of drug development failure. This is mainly due to the lengthy and expensive process of developing new drugs and the high degree of uncertainty in the outcome. On the one hand, the progress of clinical trials of new drug development is affected by multiple factors. When recruiting patients and determining clinical trial institutions, pharmaceutical companies may encounter difficulties due to factors such as the number of enrolled patients, defining eligibility criteria, and competitors conducting similar clinical trials at the same time, thus hindering the completion of clinical trials as scheduled. The Company may encounter a variety of unforeseen events during the progress of clinical trials that may delay clinical progress and hinder the regulatory approval of products under development, all of which may have a material adverse effect on the Company's business. On the other hand, industry practice shows that even if some candidate drugs have made progress in preclinical research and initial clinical trials, due to various reasons, they may not show ideal safety and efficacy in the later stages of clinical trials, or even directly lead to Project failed.

Smoking and tobacco consumption increase

According to the National Cancer Institute and the American Cancer Society, smoking causes about half of bladder cancer cases, and smokers are three times more likely to develop bladder cancer than nonsmokers. In recent years, the number of smokers worldwide has been increasing, which has increased the number of bladder cancer patients. Global smoking rates have declined steadily since 1990, according to the Global Burden of Disease Collaborative.

Region Overview:

In global comparison, a significant portion of the revenue was generated in USA (49.56% in 2022).

Company Overview:

Merck & Co. Inc. is one of the major players operating in the Bladder Cancer market, holding a share of 27.32% in 2022.

Merck & Co. Inc.

Merck & Co, known as Merck outside the United States and Canada, is an American pharmaceutical company and one of the largest pharmaceutical companies in the world. Merck has been inventing for life for more than a century, providing medicines and vaccines for many of the world's most challenging diseases. Through Merck's prescription drugs, vaccines, biotherapeutics and animal health products, Merck partners with customers and operates in more than 140 countries to provide innovative health solutions. Merck has also demonstrated its commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardiometabolic diseases, emerging animal diseases, Alzheimer's disease and including HIV infectious diseases, including Ebola.

Bristol-Myers Squibb Company

Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. Bristol-Myers Squibb's medicines help millions of patients worldwide in disease areas such as oncology, cardiovascular, immunoscience, fibrosis and more. Bristol-Myers Squibb has built a sustainable pipeline of potential therapies and is using translational medicine and data analytics to understand how Bristol-Myers Squibb can deliver the right medicine to the right patient at the right time for optimal outcomes.

Segmentation Overview:

By type, Non-Muscle-Invasive Bladder Cancer segment accounted for the largest share of market in 2022.

Non-Muscle-Muscle-Invasive Bladder Cancer

The non-Muscle-Muscle-Invasive Bladder Cancer type is the most common type of bladder cancer, and it starts in the cells inside the bladder.

Muscle-Invasive Bladder Cancer

Muscle-invasive bladder cancer is when the cancer has grown into deeper layers of the bladder wall. These are more likely to spread to other organs and are harder to treat.

Application Overview:

In the Bladder Cancer market, 49.39% of the total value was generated through the Hospital segment by application in 2022.

Key Companies in the global Bladder Cancer market covered in Chapter 3:

F. Hoffmann-La Roche AG
Pfizer Inc.
AstraZeneca Plc.
Bristol-Myers Squibb Company
Merck & Co. Inc.

In Chapter 4 and Chapter 14.2, on the basis of types, the Bladder Cancer market from 2018 to 2029 is primarily split into:

Non-Muscle-Invasive Bladder Cancer
Muscle-Invasive Bladder Cancer

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Bladder Cancer market from 2018 to 2029 covers:

Hospital
Clinic
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)